These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15102098)

  • 1. CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease.
    Newman B; Cescon D; Domenchini A; Siminovitch KA
    J Invest Dermatol; 2004 Apr; 122(4):1054-6. PubMed ID: 15102098
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder.
    Wise CA; Gillum JD; Seidman CE; Lindor NM; Veile R; Bashiardes S; Lovett M
    Hum Mol Genet; 2002 Apr; 11(8):961-9. PubMed ID: 11971877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratin mutations and intestinal pathology.
    Owens DW; Lane EB
    J Pathol; 2004 Nov; 204(4):377-85. PubMed ID: 15495267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients.
    Owens DW; Wilson NJ; Hill AJ; Rugg EL; Porter RM; Hutcheson AM; Quinlan RA; van Heel D; Parkes M; Jewell DP; Campbell SS; Ghosh S; Satsangi J; Lane EB
    J Cell Sci; 2004 Apr; 117(Pt 10):1989-99. PubMed ID: 15090596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease.
    Büning C; Halangk J; Dignass A; Ockenga J; Deindl P; Nickel R; Genschel J; Landt O; Lochs H; Schmidt H; Witt H
    Dig Liver Dis; 2004 Jun; 36(6):388-91. PubMed ID: 15248378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of an association of the IBD2 locus gene keratin 8 and inflammatory bowel disease in a large genetic association study.
    de Jong DJ; Drenth JP
    Dig Liver Dis; 2004 Jun; 36(6):380-3. PubMed ID: 15248376
    [No Abstract]   [Full Text] [Related]  

  • 8. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene.
    Hong JB; Su YN; Chiu HC
    J Am Acad Dermatol; 2009 Sep; 61(3):533-5. PubMed ID: 19700023
    [No Abstract]   [Full Text] [Related]  

  • 9. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel PSTPIP1 gene mutation in a patient with pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome.
    Lindwall E; Singla S; Davis WE; Quinet RJ
    Semin Arthritis Rheum; 2015 Aug; 45(1):91-3. PubMed ID: 25845478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation.
    Palanivel JA; Macbeth AE; Levell NJ
    Clin Exp Dermatol; 2013 Jan; 38(1):44-6. PubMed ID: 22607468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
    Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
    Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial ulcerative pyoderma gangrenosum: a report of 2 kindred.
    Alberts JH; Sams HH; Miller JL; King LE
    Cutis; 2002 Jun; 69(6):427-30. PubMed ID: 12078842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease.
    Funayama Y; Kumagai E; Takahashi K; Fukushima K; Sasaki I
    Dis Colon Rectum; 2009 Feb; 52(2):311-4. PubMed ID: 19279428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case study: diagnosis and treatment of pyoderma gangrenosum.
    Burton J
    Br J Nurs; 2005 Sep 8-21; 14(16):S10-3. PubMed ID: 16215496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies.
    van der Linde K; Boor PP; Houwing-Duistermaat JJ; Crusius BJ; Wilson PJ; Kuipers EJ; de Rooij FW
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):449-59. PubMed ID: 17489054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of pyoderma gangrenosum (PG): an updated review.
    Braswell SF; Kostopoulos TC; Ortega-Loayza AG
    J Am Acad Dermatol; 2015 Oct; 73(4):691-8. PubMed ID: 26253362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of new co-factors in 49 patients with pyoderma gangrenosum.
    Al Ghazal P; Körber A; Klode J; Dissemond J
    J Dtsch Dermatol Ges; 2012 Apr; 10(4):251-7. PubMed ID: 21762379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of leukocytapheresis using a centrifugal cell separator for steroid-resistant pyoderma gangrenosum associated with inflammatory bowel disease.
    Hanafusa T; Azukizawa H; Umegaki N; Tani M; Yamaguchi Y; Katayama I
    J Dermatol; 2011 May; 38(5):507-10. PubMed ID: 21352279
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease.
    Hayashi H; Kuwabara C; Tarumi K; Makino E; Fujimoto W
    J Dermatol; 2012 Jun; 39(6):576-8. PubMed ID: 21958000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.